Abstract
The aim of this study is to evaluate the efficacy and safety of subconjunctival bevacizumab injection(s) in the treatment of impending recurrent pterygia. Twenty-three eyes of 23 patients who developed impending recurrence after pterygium surgery with conjunctival autografting and were treated with subconjunctival bevacizumab injection(s) (2.5 mg/0.1 mL) were included in the study. Anterior segment photographs were taken prior to and at 1 week, 1, 3 and 6 months after the injection, and at the end of the follow-up period. Image analysis was performed using an image processing and analysis software program. Recurrence rate and complications were recorded. The mean age and follow-up time of the patients were 51.2 ± 6.2 (31–60 years) and 16.8 ± 3.1 (12–22 months), respectively. The average number of injections was 2 ± 0.78 (1–3). Sixteen eyes required re-injection (two injections in nine eyes, three injections in seven eyes), due to progression of vascularization. There were significant differences between size percentage of lesions before injection and at 1 week, 1, 3 and 6 months after the injection (p < 0.05 for all). Corneal recurrence developed in only one patient and no ocular or systemic side-effects of bevacizumab were observed. Repeated injections of bevacizumab may help to prevent the high recurrence rate of residual impending pterygium, due to its adjuvant role in decreasing lesion size, especially in the first year after surgery.
Similar content being viewed by others
References
Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A (2008) Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33:23–28
Hosseini H, Nejabat M, Khalili MR (2007) Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 69:925–927
Mansour AM (2009) Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol 93:864–865
Teng CC, Patel NN, Jacobson L (2009) Effect of subconjunctival bevacizumab on primary pterygium. Cornea 28:468–470
Kria L, Ohira A, Amemiya T (1996) Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem 98:195–201
Lee DH, Cho HJ, Kim JT et al (2001) Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 20:738–742
Jin J, Guan M, Sima J et al (2003) Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 22:473–477
Gebhardt M, Mentlein R, Schaudig U et al (2005) Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 112:1023–1030
Prabhasawat P, Tesavibul N, Leelapatranura K et al (2006) Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology 113:1102–1109
Cardillo JA, Alves MR, Ambrosio LE et al (1995) Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. Ophthalmology 102:1949–1952
Hosseini H, Nejabat M, Mehyar M et al (2007) Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 35:745–748
Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545–2552
Manzano RP, Peyman GA, Khan P et al (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91:804–807
Kim TI, Kim SW, Kim S et al (2008) Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 27:349–352
Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577–1579
FallahTafti MR, Khosravifard K, Mohammadpour M et al (2011) Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea 30:127–129
Wu PC, Kuo HK, Tai MH et al (2009) Topical bevacizumab eyedrops for limbal-conunctival neovascularization in impending recurrent pterygium. Cornea 28:103–104
Fallah MR, Khosravi K, Hashemian MN et al (2010) Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 35:17–22
Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P (2012) Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium. Cornea 31:155–161
Prabhasawat P, Barton K, Burkett G et al (1997) Comparison of conjunctival autografts, amniotic membrane grafts and primary closure for pterygium excision. Ophthalmology 104:974–985
Shenasi A, Mousavi F, Shoa-Ahari S, Rahmi-Ardabili B, Fouladi RF (2011) Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea 30:1219–1222
Bahar I, Kaiserman I, McAllum P et al (2008) Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27:142–147
Papathanassiou M, Theodossiadis PG, Liakaros VS et al (2008) Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 145:424–431
You IC, Kang IS, Lee SH, Yoon KC (2009) Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 87:653–658
Koenig Y, Bock F, Horn F et al (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:1375–1382
Hurmeric V, Mumcuoglu T, Erduman C et al (2008) Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 27:357–362
Hirst LW, Sebban A, Chant D (1994) Pterygium recurrence time. Ophthalmology 101:755–758
Conflict of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bayar, S.A., Kucukerdonmez, C., Oner, O. et al. Subconjunctival bevacizumab in the impending recurrent pterygia. Int Ophthalmol 34, 541–547 (2014). https://doi.org/10.1007/s10792-013-9852-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-013-9852-1